Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Entero-Insular Axis

Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · see citing works

Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects

Nathan, D. M., Schreiber, E., Fogel, H., Mojsov, S., & Habener, J. F. (1992) · Diabetes Care · doi:10.2337/diacare.15.2.270 · Cited by 289 · see citing works

Biology of Incretins: GLP-1 and GIP

Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Glucagon-like peptide 1 (GLP-1)

Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036 · see citing works

The Discovery and Development of Liraglutide and Semaglutide

Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · see citing works

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · see citing works

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · see citing works

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

GIP and GLP-1, the two incretin hormones: Similarities and differences

Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · see citing works

Sensory neurons that detect stretch and nutrients in the digestive system

Williams, E. K., Chang, R. B., Strochlic, D. E., Umans, B. D., Lowell, B. B., & Liberles, S. D. (2016) · Cell · doi:10.1016/j.cell.2016.05.011 · Cited by 645 · see citing works

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · see citing works

Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain

Chang, C.-P., Pearse, R. V., O'Connell, S., & Rosenfeld, M. G. (1993) · Neuron · doi:10.1016/0896-6273(93)90230-o · Cited by 537 · see citing works

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway

Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · see citing works

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain.

Usdin, T. B., Mezey, E., Button, D. C., Brownstein, M. J., & Bonner, T. I. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243312 · Cited by 534 · see citing works

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats

Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · see citing works

GLP-1 physiology informs the pharmacotherapy of obesity

Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · see citing works

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 503 · see citing works

Identification and characterization of GLP-1 receptor–expressing cells using a new transgenic mouse model

Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

The New Biology and Pharmacology of Glucagon

Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419 · see citing works

Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · see citing works

Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor

Buteau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411 · see citing works

The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update

Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · see citing works

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · see citing works

Cardiovascular Actions of Incretin-Based Therapies

Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358 · see citing works

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · see citing works

GLP-1 Receptor Expression Within the Human Heart

Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · see citing works

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315 · see citing works

Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation

McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · see citing works

The structure and function of the glucagon‐like peptide‐1 receptor and its ligands

Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292 · see citing works

Regulation of Glucose Homeostasis by GLP-1

Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287 · see citing works

Area postrema cell types that mediate nausea-associated behaviors

Zhang, C., Kaye, J. A., Cai, Z., Wang, Y., Prescott, S. L., & Liberles, S. D. (2021) · Neuron · doi:10.1016/j.neuron.2020.11.010 · Cited by 263 · see citing works

Glucagonlike peptide 1: a newly discovered gastrointestinal hormone

Holst, J. J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90831-1 · Cited by 252 · see citing works

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265 · see citing works

The incretin system in healthy humans: The role of GIP and GLP-1

Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248 · see citing works

Glucagon-like peptide analogues for type 2 diabetes mellitus

Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · see citing works

Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach

Dimitriadis, G. D., Maratou, E., Kountouri, A., Board, M., & Lambadiari, V. (2021) · Nutrients · doi:10.3390/nu13010159 · Cited by 241 · see citing works

VAMP‐2 and cellubrevin are expressed in pancreatic beta‐cells and are essential for Ca(2+)‐but not for GTP gamma S‐induced insulin secretion.

Regazzi, R., Wollheim, C. B., Lang, J., Theler, J. M., Rossetto, O., Montecucco, C., Sadoul, K., Weller, U., Palmer, M., & Thorens, B. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07273.x · Cited by 233 · see citing works

Small-molecule agonists for the glucagon-like peptide 1 receptor

Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · see citing works

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist

Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · see citing works

cAMP-dependent Mobilization of Intracellular Ca2+ Stores by Activation of Ryanodine Receptors in Pancreatic β-Cells

Holz, G. G., Leech, C. A., Heller, R. S., Castonguay, M., & Habener, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.14147 · Cited by 220 · see citing works

Defective Glucose-Dependent Insulinotropic Polypeptide Receptor Expression in Diabetic Fatty Zucker Rats

Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208 · see citing works

Suppression of glucose production by GLP-1 independent of islet hormones: A novel extrapancreatic effect

Prigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199 · see citing works

Metabolic messengers: glucagon-like peptide 1

Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199 · see citing works

Activation of a cAMP-regulated Ca2+-Signaling Pathway in Pancreatic β-Cells by the Insulinotropic Hormone Glucagon-like Peptide-1

Holz, G. G., Leech, C. A., & Habener, J. F. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.17749 · Cited by 188 · see citing works

A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor

Griffith, D. A., Edmonds, D. J., Fortin, J.-P., Kalgutkar, A. S., Kuzmiski, J. B., Loria, P. M., Saxena, A. R., Bagley, S. W., Buckeridge, C., Curto, J. M., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01856 · Cited by 192 · see citing works

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology &amp; Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171 · see citing works

Approach to the patient with mody-monogenic diabetes

Broome, D. T., Pantalone, K. M., Kashyap, S. R., & Philipson, L. H. (2021) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/clinem/dgaa710 · Cited by 159 · see citing works

Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment

Trapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154 · see citing works

The Glucagon-Like Peptide-1 Receptor—or Not?

Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154 · see citing works

Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases

Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148 · see citing works

Regulation of Adipocyte Formation by GLP-1/GLP-1R Signaling

Challa, T. D., Beaton, N., Arnold, M., Rudofsky, G., Langhans, W., & Wolfrum, C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.310342 · Cited by 149 · see citing works

Neural contribution to the effect of glucagon-like peptide-1-(7—36) amide on arterial blood pressure in rats

Barragán, J. M., Eng, J., Rodríguez, R., & Blázquez, E. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e784 · Cited by 142 · see citing works

Glucagon-Like Peptide 1 Interacts with Ghrelin and Leptin to Regulate Glucose Metabolism and Food Intake through Vagal Afferent Neuron Signaling ,

Ronveaux, C. C., Tomé, D., & Raybould, H. E. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.206029 · Cited by 124 · see citing works

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125 · see citing works

Glucose and GLP-1 Stimulate cAMP Production via Distinct Adenylyl Cyclases in INS-1E Insulinoma Cells

Ramos, L. S., Zippin, J. H., Kamenetsky, M., Buck, J., & Levin, L. R. (2008) · The Journal of General Physiology · doi:10.1085/jgp.200810044 · Cited by 118 · see citing works

The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders

McIntyre, R. S., Powell, A. M., Kaidanovich-Beilin, O., Soczynska, J. K., Alsuwaidan, M., Woldeyohannes, H. O., Kim, A. S., & Gallaugher, L. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.021 · Cited by 110 · see citing works

Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action

Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104 · see citing works

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism

Andreozzi, F., Raciti, G. A., Nigro, C., Mannino, G. C., Procopio, T., Davalli, A. M., Beguinot, F., Sesti, G., Miele, C., & Folli, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0985-7 · Cited by 102 · see citing works

GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway

Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101 · see citing works

Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction.

Gorn, A. H., Rudolph, S. M., Flannery, M. R., Morton, C. C., Weremowicz, S., Wang, T. Z., Krane, S. M., & Goldring, S. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117970 · Cited by 100 · see citing works

Glucagon-like peptides 1 and 2 in health and disease: A review

Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100 · see citing works

Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule

Ben Nasr, M., Usuelli, V., Dellepiane, S., Seelam, A. J., Fiorentino, T. V., D’Addio, F., Fiorina, E., Xu, C., Xie, Y., Balasubramanian, H. B., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.001 · Cited by 102 · see citing works

Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—the role of the GLP-1 receptor

Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99 · see citing works

Glucagon-Like Peptide-1 Receptor Knockout Mice Are Protected from High-Fat Diet-Induced Insulin Resistance

Ayala, J. E., Bracy, D. P., James, F. D., Burmeister, M. A., Wasserman, D. H., & Drucker, D. J. (2010) · Endocrinology · doi:10.1210/en.2010-0289 · Cited by 95 · see citing works

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective

Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94 · see citing works

Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice

Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95 · see citing works

Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating

Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92 · see citing works

Obesity: pathophysiology and therapeutic interventions

Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., & Nian, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00264-9 · Cited by 89 · see citing works

The Emerging Role of Polyphenols in the Management of Type 2 Diabetes

Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88 · see citing works

Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14

Klinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B. (2008) · Diabetes · doi:10.2337/db07-1414 · Cited by 86 · see citing works

Molecular cloning and functional expression of a third isoform of the human calcitonin receptor and partial characterization of the calcitonin receptor gene.

Albrandt, K., Brady, E. M., Moore, C. X., Mull, E., Sierzega, M. E., & Beaumont, K. (1995) · Endocrinology · doi:10.1210/endo.136.12.7588285 · Cited by 88 · see citing works

Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress

Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84 · see citing works

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide

McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84 · see citing works

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy

Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80 · see citing works

Epac2-Dependent Rap1 Activation and the Control of Islet Insulin Secretion by Glucagon-Like Peptide-1

Leech, C. A., Chepurny, O. G., & Holz, G. G. (2010) · Vitamins &amp; Hormones · doi:10.1016/b978-0-12-381517-0.00010-2 · Cited by 76 · see citing works

Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats

Sancho, V., Trigo, M. V., González, N., Valverde, I., Malaisse, W. J., & Villanueva-Peñacarrillo, M. L. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01747 · Cited by 78 · see citing works

GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74 · see citing works

Expression of glucagon‐like peptide 1 receptor in a murine C cell line Regulation of calcitonin gene by glucagon‐like peptide 1

Lamari, Y., Boissard, C., Moukhtar, M. S., Jullienne, A., Rosselin, G., & Garel, J.-M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00895-2 · Cited by 73 · see citing works

GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far

Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68 · see citing works

Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop

Mathi, S. K., Chan, Y., Li, X., & Wheeler, M. B. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.4.9913 · Cited by 71 · see citing works

Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line.

Crespel, A., De Boisvilliers, F., Gros, L., & Kervran, A. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756532 · Cited by 67 · see citing works

Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction

Liu, C., Carvalho, A., & McIntyre, R. (2015) · CNS &amp; Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130204031 · Cited by 61 · see citing works

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63 · see citing works

Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes

Dalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60 · see citing works

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity

Green, B., Mooney, M., Gault, V., Irwin, N., Bailey, C., Harriott, P., Greer, B., O'Harte, F., & Flatt, P. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800379 · Cited by 57 · see citing works

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52 · see citing works

An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke

Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0148827 · Cited by 50 · see citing works

Glucagon stimulates expression of the inducible cAMP early repressor and suppresses insulin gene expression in pancreatic beta-cells.

Hussain, M. A., Daniel, P. B., & Habener, J. F. (2000) · Diabetes · doi:10.2337/diabetes.49.10.1681 · Cited by 40 · see citing works

Reagents and models for detecting endogenous GLP1R and GIPR

Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40 · see citing works

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline

Irwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.022 · Cited by 38 · see citing works

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

Arredouani, A. (2025) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36 · see citing works

Glucagon‐like peptide‐1: modulator of <i>β</i> ‐cell dysfunction and death

Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32 · see citing works

Glucose-dependent alterations of intracellular free calcium by glucagon-like peptide-1(7-36amide) in individual mouse β-cells

Cullinan, C. A., Brady, E. J., Saperstein, R., & Leibowitz, M. D. (1994) · Cell Calcium · doi:10.1016/0143-4160(94)90014-0 · Cited by 29 · see citing works

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40 · see citing works

GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action

Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26 · see citing works

On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects

HOLST, J. J., TOFT-NIELSEN, M.-B., ØRSKOV, C., NAUCK, M., & WILLMS, B. (2006) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb17549.x · Cited by 21 · see citing works